Compare T & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | T | AZN |
|---|---|---|
| Founded | 1983 | 1992 |
| Country | United States | United Kingdom |
| Employees | 268000 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3B | 316.4B |
| IPO Year | 2015 | 1995 |
| Metric | T | AZN |
|---|---|---|
| Price | $24.79 | $156.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $30.55 | N/A |
| AVG Volume (30 Days) | ★ 58.1M | 3.8M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.31% | 1.73% |
| EPS Growth | ★ 104.03 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $125,648,000,000.00 | N/A |
| Revenue This Year | $4.34 | $10.34 |
| Revenue Next Year | $2.14 | $6.43 |
| P/E Ratio | ★ $20.73 | $31.91 |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $19.89 | $72.90 |
| 52 Week High | $29.79 | $212.71 |
| Indicator | T | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 34.53 |
| Support Level | $23.93 | $153.41 |
| Resistance Level | $25.24 | $175.04 |
| Average True Range (ATR) | 0.53 | 2.73 |
| MACD | 0.11 | -0.25 |
| Stochastic Oscillator | 88.03 | 14.14 |
The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential services, about 11% of revenue, primarily consist of in-home broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 25 million wireless customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.